Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | JAK1 | P23458 | 8/20 | 0.43 |
| ▸ | TYK2 | P29597 | 6/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956630 | 0.84 | TBXA2R (0.34) | JAK2JAK1TYK2ROCK2TBXA2R | |
| SCHEMBL5956732 | 0.82 | ROCK2 (0.40) | ROCK2TBXA2RACHENAAAROCK1 | |
| SCHEMBL2855651 | 0.80 | PRKCI (0.36) | JAK2JAK1TYK2JAK3ROCK2 | |
| SCHEMBL4442286 | 0.80 | PRKCI (0.36) | JAK2JAK1TYK2JAK3ROCK2 | |
| SCHEMBL5956731 | 0.80 | DGAT1 (0.33) | JAK2JAK1TYK2ROCK2TBXA2R | |
| SCHEMBL5956854 | 0.77 | TBXA2R (0.48) | TBXA2RACHENAAA | |
| SCHEMBL5956646 | 0.76 | POLB (0.51) | ROCK2 | |
| SCHEMBL5956589 | 0.75 | JAK2 (0.45) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL5956584 | 0.75 | JAK2 (0.45) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL5956658 | 0.74 | ALDH1A1 (0.44) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | JAK2 585/4885JAK1 490/4885TYK2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.